中农发种业集团股份有限公司控股子公司河南农化2026年度日常关联交易公告深度解读
一、公告要点概述
- 关联交易内容：中农发种业集团股份有限公司（简称“中农发种业”）控股子公司河南农化将在2026年度与其第二大股东北京颖泰嘉和生物科技股份有限公司（简称“北京颖泰”）及其下属公司，开展设备及原材料采购和化工产品销售的日常关联交易。
- 交易金额：2026年度预计关联交易总金额为30,800万元，包括向北京颖泰及其下属公司采购化工设备和原材料800万元，以及向其销售化工产品30,000万元。
- 股东会审议：该关联交易事项需提交公司股东大会审议。
- 定价原则：交易价格以市场价格为基础，遵循公平、合理原则，由双方协商确定。
- 对公司影响：公告强调，本次交易不会影响公司的独立性，不会导致对关联方的依赖或被其控制。
二、详细内容与投资者需关注事项
1. 交易背景与必要性说明
河南农化与北京颖泰的合作属于正常业务采购与销售，有助于充分利用关联方的资源和条件优势，保障产品质量，促进生产经营有序进行，有利于公司良性发展。
2. 前次交易回顾与金额变化
- 2025年度预计采购金额200万元，实际仅11.23万元，主要由于相关业务调整，部分采购项目未能达成。
- 2025年度预计销售金额33,800万元，实际为19,662万元，受市场行情及业务调整影响，销量和售价未达预期。
- 2026年度采购金额显著提升至800万元，销售金额为30,000万元，显示公司对未来市场行情持乐观预期。
3. 关联方介绍
- 北京颖泰嘉和生物科技股份有限公司：注册资本12.258亿元，2025年9月30日总资产114.96亿元，净资产50.47亿元，2025年营业收入42.66亿元，净利润-1,163.13万元，资产负债率56.10%。
- 北京颖泰为河南农化第二大股东，自2019年起持有其20%股权。
- 公司运营正常，具备良好履约能力。
4. 关联交易的具体安排及影响
- 向北京颖泰及下属公司采购化工设备和原材料（预计采购加氢反应、分离提纯设备及产品原料）。
- 向北京颖泰及下属公司销售化工产品，预计对关联方销量增加。
- 本次关联交易有助于扩大销售规模，优化采购渠道，提升整体经营效率。
5. 独立董事及公司意见
独立董事全票通过该事项，认为符合公司及全体股东利益，不损害中小股东权益，建议提交董事会审议。
三、投资者需重点关注的潜在影响与价格敏感信息
- 2026年度对北京颖泰及下属公司销售规模大幅提升，若能实现，将显著带动河南农化业绩增长，利好公司未来盈利能力。
- 相关交易仍需股东大会审议，投资者应关注后续决议进展。
- 北京颖泰作为上市公司，财务状况良好（尽管2025年小幅亏损），具备长期合作基础，降低交易履约风险。
- 若市场行情波动或关联方业务调整，可能导致实际交易金额与预计存在差异。
- 公司强调不会因此对关联方产生依赖或被其控制，维护公司独立性。
四、结论
此次公告中披露的关联交易金额大、涉及公司主营业务，若执行顺利，对公司业绩提升具有积极推动作用。建议投资者重点关注相关交易执行情况及股东大会表决结果，该事项具备一定价格敏感性，可能对公司股价产生影响。
免责声明：本文仅作为信息披露与分析参考，不构成任何投资建议。投资有风险，决策需谨慎。
In-depth Report: Sinofarm Seed Industry Group’s 2026 Related-Party Transactions with Beijing Yingtai Jiahe
Key Highlights
- Transaction Parties: Sinofarm Seed Industry Group (control subsidiary Henan Agrochemical) and its second-largest shareholder, Beijing Yingtai Jiahe Biotech (and its subsidiaries).
- Transaction Amount: Estimated total of RMB 308 million in 2026, comprising RMB 8 million in procurement and RMB 300 million in product sales.
- Approval Process: Transaction to be submitted for shareholder meeting approval.
- Pricing Policy: Market-based, fair and reasonable, through bilateral negotiation.
- Impact: The company states these transactions will not affect independence or create dependence on the related party.
Details & Investor-Important Issues
1. Transaction Background and Rationale
The collaboration between Henan Agrochemical and Beijing Yingtai is a regular business activity, leveraging related-party resources to ensure product quality, orderly operations, and sustainable development.
2. Previous Year Comparison
- 2025 planned procurement: RMB 2 million, actual: RMB 112,300 (due to business adjustment, some projects were not completed).
- 2025 planned sales: RMB 338 million, actual: RMB 196.62 million (market and business changes led to lower than expected sales and prices).
- 2026 plans for procurement and sales show a major increase, signaling optimism for market recovery and business growth.
3. Related Party Profile
- Beijing Yingtai Jiahe: RMB 1.2258 billion registered capital, as of Sept 2025, total assets RMB 11.496 billion, net assets RMB 5.047 billion, 2025 revenue RMB 4.266 billion, 2025 net loss RMB 11.63 million, debt ratio 56.1%.
- Since 2019, holds 20% of Henan Agrochemical shares; recognized as related party by exchange rules.
- Normal operations and strong performance, good contract fulfillment capacity.
4. Specific Arrangements and Impact
- Procurement: hydrogenation reaction, separation, purification equipment, and raw materials from Yingtai and subsidiaries.
- Sales: increased delivery of chemical products to Yingtai and subsidiaries, anticipating higher transaction volume.
- Benefits: scale expansion, procurement channel optimization, efficiency improvement.
5. Independent Director and Company View
Approved unanimously by independent directors; deemed beneficial to company and all shareholders, with no harm to minority shareholders. Recommended for board approval.
Investor Takeaways and Price-Sensitive Issues
- Substantial increase in planned related transactions for 2026 could significantly boost business revenue and earnings if realized.
- Shareholders should follow the outcome of shareholder meeting approvals and transaction progress.
- Yingtai’s financial health (despite a minor 2025 loss) and status as a listed entity lower counterparty risk.
- Market volatility or partner business changes could affect actual versus planned amounts.
- Company independence is maintained, with no dependency or control by related parties.
Conclusion
The disclosed related transactions are sizable and core to company business. If completed, they will materially impact performance, making this a price-sensitive event. Investors are advised to monitor execution and shareholder meeting outcomes.
Disclaimer: This article is for informational and analytical purposes only, and does not constitute investment advice. Investment involves risk. Please make decisions cautiously.
View 农发种业 Historical chart here
